Home/Small Molecules/GPCRs & Receptor Biology

GPCRs & Receptor Biology

G-protein-coupled, nuclear and other ligand-binding receptors and their modulators.

Browse all research categories

Browse by research category

Products may appear in more than one category. Counts refer to distinct catalog numbers within each category.

Other Research Tools (75) · Additional reagents, building blocks and specialized research tools.

GPCRs & Receptor Biology products

Combine a keyword, research category and target to narrow the product list.

Loading catalog filters…

1,219 products · Showing 769–816

DC28977

L-798106

CAS 244101-02-8

L-798106 is potent and highly selective prostanoid EP3 receptor antagonist (Ki=0.3 nM), it also has micromolar activities at the EP4, EP1 and EP2 receptors with Ki values of 916 nM, >5000 nM and >5000 nM at EP4, EP1 and EP2, respectively[1].

L-798106 chemical structure
DC8378

Mavatrep(JNJ-39439335)

CAS 956274-94-5

Mavatrep is an orally bioavailable TRPV1 antagonist (Ki=6.5 nM), exhibits minimal effect on the enzymatic activity (IC50 > 25 μM) of CYP isoforms 3A4, 1A2, and 2D6.IC50 value: 6.5 nM (Ki, for TRPV1)Target: TRPV1in vitro: Mavatrep exhibits superior pharmacodynamic properties. In a TRPV1 functional assay, using cells expressing recombinant human TRPV1 channels, Mavatrep antagonizes capsaicin-induced Ca2+ influx, with an IC50 value of 4.6 nM. Mavatrep blocks the activation of hTRPV1 channels by Capsaicin (1 μM) and by pH (5.0) in a concentration-dependent fashion, with IC50 values of 23 and 6.8 nM, respectively. in vivo: Mavatrep exhibits superior pharmacodynamic properties in the CFA model of inflammatory pain.

Mavatrep(JNJ-39439335) chemical structure
DC8765

AM251

CAS 183232-66-8

AM251 is a selective cannabinoid 1 (CB1) receptor antagonist with an IC50 of 8 nM, also acts as a potent GPR55 agonist with an EC50 of 39 nM.

AM251 chemical structure
DC23610

CP-339818 hydrochloride

CAS 478341-55-8

CP-339818 is a potent, selective, non-peptide KV1.3 channel antagonist with IC50 of 200 nM; displays selectivity over Kv1.1, Kv1.2, Kv1.5, Kv1.6, Kv3.1-4, and Kv4.2, with only exception Kv1.4 (IC50=300 nM), also has no effect on T cell channels (I(CRAC) and intermediate-conductance K(Ca)); inhibits Kv1.3 in a use-dependent manner by preferentially blocking the C-type inactivated state of the channel; suppresses human T cell activation.

CP-339818 hydrochloride chemical structure
DC11748

LY2033298

CAS 886047-13-8

A potent, selective, positive allosteric modulator of muscarinic M4 receptors; directly potentiates agonist binding while having minimal effects on antagonist binding; enhances inhibition by oxotremorine of light-induced phase shifts in hamster circadian activity rhythms, shows antipsychotic activity in vivo.

LY2033298 chemical structure
DC45531

ICCB-19 hydrochloride

CAS 1803605-68-6

ICCB-19 hydrochloride is an inhibitor of TNFRSF1A Associated Via Death Domain (TRADD) with IC50 of 1.12 μM and 2.01 μM for protecting Velcade-induced apoptosis in Jurkat cells and protecting RDA in MEFs, respectively. ICCB-19 indirectly inhibits Receptor-interacting serine/threonine-protein kinase 1 (RIPK1). ICCB-19 effectively induces autophagy.

ICCB-19 hydrochloride chemical structure
DC7754

ZK-200775

CAS 161605-73-8

ZK 200775 is a competitive GluR (AMPA)/kainate antagonist. In rat cortical membranes, it displays high affinity for [3H]-AMPA (Ki = 120 nM) and [3H]-CNQX (Ki = 32 nM) binding sites but low affinity for kainate and NMDA channel-associated binding sites (IC50 values range from 2.5 to 11 μM). It inhibits currents induced by AMPA, kainate and NMDA with IC50 values of 21 nM, 27 nM, and > 1 μM respectively. AMPA is a transmembrane glutamate receptor composed of the subunits GluR-1,2,3,4.. For the detailed information of ZK-200775, the solubility of ZK-200775 in water, the solubility of ZK-200775 in DMSO, the solubility of ZK-200775 in PBS buffer, the animal experiment (test) of ZK-200775, the cell expriment (test) of ZK-200775, the in vivo, in vitro and clinical trial test of ZK-200775, the EC50, IC50,and affinity,of ZK-200775, Please contact DC Chemicals.

ZK-200775 chemical structure
DC8878

SB 242084

CAS 181632-25-7

SB 242084 is a potent and selective antagonist of 5-HT2C receptor. It increases the basal activity of dopaminergic neurons and affects the behavioral responses mediated by 5-HT2C such as mesolimbic neuron activity and food intake.

SB 242084 chemical structure
DCAPI1584

Roxatidine Acetate Hydrochloride

CAS 93793-83-0

For the detailed information of Roxatidine Acetate Hydrochloride, the solubility of Roxatidine Acetate Hydrochloride in water, the solubility of Roxatidine Acetate Hydrochloride in DMSO, the solubility of Roxatidine Acetate Hydrochloride in PBS buffer, the animal experiment(test) (test) of Roxatidine Acetate Hydrochloride, the cell expriment (test) of Roxatidine Acetate Hydrochloride, the in vivo, in vitro and clinical trial test of Roxatidine Acetate Hydrochloride, the EC50, IC50,and Affinity of Roxatidine Acetate Hydrochloride,, please contact DC Chemicals.

Roxatidine Acetate Hydrochloride chemical structure
DC7452

LDN-211904

CAS 1198408-78-4

A pyrazolo[1,5-a]pyridine derivative that acts as an potent and reversible EphB3 receptor tyrosine kinase inhibitor with an IC50 of 79 nM with good mouse liver microsomal stability and aqueous solubility. Shown to suppress EphB3-induced autophosphorylation of EphB3 receptor at 10 µM in cells. When profiled against a panel of 288 kinases at 5 µM, found to also inhibit most of the Eph (Erythropoietin-producing hepatocellular carcinoma) receptor kinases including EphA1, EphA2, EphA3, EphA4, EphA5, EphA8, EphB1, EphB2, EphB3, EphB4 and other tyrosine kinases, but not EphA6 and EphA7, and is non-inhibitory towards non-RTK kinases screened except For p38α, p38β, and Qik.For the detailed information of LDN-211904, the solubility of LDN-211904 in water, the solubility of LDN-211904 in DMSO, the solubility of LDN-211904 in PBS buffer, the animal experiment (test) of LDN-211904, the cell expriment (test) of LDN-211904, the in vivo, in vitro and clinical trial test of LDN-211904, the EC50, IC50,and Affinity of LDN-211904, Please contact DC Chemicals.

LDN-211904 chemical structure
DC8543

CP465022 HCl

CAS 199655-36-2

CP 465022 hydrochloride is a selective GluR (AMPA) antagonist which is non-competitive. GluR (AMPA) is a transmembrane glutamate receptor composed of the subunits GluR-1,2,3,4.

CP465022 HCl chemical structure
DC6310

AMG 853(AMG853;Vidupiprant)

CAS 1169483-24-2

AMG 853 is novel a CRTH2 and DP Dual Antagonist.For the detailed information of AMG 853(AMG853;Vidupiprant), the solubility of AMG 853(AMG853;Vidupiprant) in water, the solubility of AMG 853(AMG853;Vidupiprant) in DMSO, the solubility of AMG 853(AMG853;Vidupiprant) in PBS buffer, the animal experiment (test) of AMG 853(AMG853;Vidupiprant), the cell expriment (test) of AMG 853(AMG853;Vidupiprant), the in vivo, in vitro and clinical trial test of AMG 853(AMG853;Vidupiprant), the EC50, IC50,and Affinity of AMG 853(AMG853;Vidupiprant), Please contact DC Chemicals.

AMG 853(AMG853;Vidupiprant) chemical structure
DC8289

Prucalopride succinate

CAS 179474-85-2

Prucalopride succinate is a selective, high affinity 5-HT4 receptor agonist with pKi of 8.6/8.1 for 5-HT4a/4b.in vitro: Prucalopride was a 5-HT(4) receptor agonist in the guinea-pig colon, as it induced contractions (pEC(50)=7.48+/-0.06; insensitive to a 5-HT(2A) or 5-HT(3) receptor antagonist, but inhibited by a 5-HT(4) receptor antagonist) as well as the facilitation of electrical stimulation-induced noncholinergic contractions (blocked by a 5-HT(4) receptor antagonist). Prucalopride did not cause relevant inhibition of 5-HT(2A), 5-HT(2B), or 5-HT(3), motilin or cholecystokinin (CCK(1)) receptor-mediated contractions, nor nicotinic or muscarinic acetylcholine receptor-mediated contractions, up to 10 microM. in vivo: Rat microdialysis studies revealed that prucalopride maximally increased ACh and histamine levels in the prefrontal cortex at 5 and 10 mg/kg, whereas PRX-03140 significantly increased cortical histamine levels at 50 mg/kg, failing to affect ACh release at doses lower than 150 mg/kg. For the detailed information of Prucalopride succinate, the solubility of Prucalopride succinate in water, the solubility of Prucalopride succinate in DMSO, the solubility of Prucalopride succinate in PBS buffer, the animal experiment (test) of Prucalopride succinate, the cell expriment (test) of Prucalopride succinate, the in vivo, in vitro and clinical trial test of Prucalopride succinate, the EC50, IC50,and affinity,of Prucalopride succinate, For the detailed information of Prucalopride succinate, the solubility of Prucalopride succinate in water, the solubility of Prucalopride succinate in DMSO, the solubility of Prucalopride succinate in PBS buffer, the animal experiment (test) of Prucalopride succinate, the cell expriment (test) of Prucalopride succinate, the in vivo, in vitro and clinical trial test of Prucalopride succinate, the EC50, IC50,and affinity,of Prucalopride succinate, Please contact DC Chemicals.

Prucalopride succinate chemical structure
DC9437

Bosentan

CAS 147536-97-8

Bosentan is a competitive and dual antagonist of endothelin-1 at the endothelin-A (ET-A) and endothelin-B (ET-B) receptors. Under normal conditions, endothelin-1 binding of ET-A or ET-B receptors causes constriction of the pulmonary blood vessels. By blocking this interaction, bosentan decreases pulmonary vascular resistance. Bosentan has a slightly higher affinity for ET-A than ET-B. Bosentan is indicated mainly for the treatment of pulmonary hypertension. In 2007, Bosentan was also approved in the European Union for reducing the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease.

Bosentan chemical structure
DC22383

Sitaxsentan

CAS 184036-34-8

A potent, long acting, orally active, selective ETA receptor antagonist that binds competitively to human ETA receptor with Ki of 0.43 nM, IC50 of 1.4 nM; dispalys >5,000-fold selectivity over ETB receptors; inhibits ET1-induced stimulation of phosphoinositide turnover with Ki of 0.686 nM, and pA2 of 8.0; excellent PK profile and oral bioavailability.HypertensionWithdrawn

Sitaxsentan chemical structure
DC22377

Pitolisant

CAS 362665-56-3

A potent and selective antagonist of H3 receptor with Ki/EC50 of 0.16/1.5 nM; no effect on H1, H2, H4 receptors (IC50>10 uM); orally bioactive.Sleep DisorderApproved

Pitolisant chemical structure
DC22622

WAY-100635

CAS 162760-96-5

A potent and selective 5-HT1A receptor antagonist; also acts as potent full agonist at the D4 receptor; completely prevents not only the hyperpolarization, with an IC50 of 1.3 nM, but also the decrease in membrane input resistance produced by 5-HT and 5-carboxamidotryptamine with IC50 of 22.5 μM and 50 nM, respectively. AnxietyPhase 1 Discontinued

WAY-100635 chemical structure
DCAPI1015

Zafirlukast(Accolate)

CAS 107753-78-6

For the detailed information of Zafirlukast(Accolate), the solubility of Zafirlukast(Accolate) in water, the solubility of Zafirlukast(Accolate) in DMSO, the solubility of Zafirlukast(Accolate) in PBS buffer, the animal experiment(test) (test) of Zafirlukast(Accolate), the cell expriment (test) of Zafirlukast(Accolate), the in vivo, in vitro and clinical trial test of Zafirlukast(Accolate), the EC50, IC50,and Affinity of Zafirlukast(Accolate),, please contact DC Chemicals.

Zafirlukast(Accolate) chemical structure
DC60134

Soporidine

CAS 1060376-43-3

Soporidine is an antagonist of germination of the parasitic plant Striga hermonthica. Soporidine specifically inhibits a S. hermonthica strigolactone receptor and inhibits the parasite's germination[1].

Soporidine chemical structure
DC20616

AA 41612

CAS 433690-62-1

AA 41612 is a potent, synthetic melanopsin antagonist with IC50 of 15.8 nM, attenuates melanopsin photocurrent in a dose-dependent manner; specifically and reversibly modifies melanopsin-dependent light responses including the pupillary light reflex and light aversion in vivo.

AA 41612 chemical structure
DC43692

SGA360

CAS 680611-86-3

SGA360 modulates inflammatory SAA1 signaling via an aryl hydrocarbon receptor (AHR)-dependent pathway, functioning as a partial antagonist through a non-canonical mechanism independent of AHR-DNA binding.

SGA360 chemical structure
DC70747

RTI-7470-44

CAS 825658-63-7

RTI-7470-44 is a highly potent and selective antagonist of the human trace amine-associated receptor 1 (hTAAR1), demonstrating an IC50 of 8.4 nM in an in vitro cAMP functional assay. In radioligand binding studies, it exhibits a Ki value of 0.3 nM, highlighting its strong affinity for hTAAR1. Notably, RTI-7470-44 shows significant species selectivity, with over 90-fold preference for hTAAR1 compared to its rat and mouse counterparts. This compound also possesses favorable pharmacokinetic properties, including good blood-brain barrier penetration, moderate metabolic stability, and a promising off-target safety profile. In electrophysiological studies, RTI-7470-44 enhanced the spontaneous firing rate of dopaminergic neurons in the mouse ventral tegmental area (VTA) and effectively counteracted the effects of the TAAR1 agonist RO5166017.

RTI-7470-44 chemical structure
DC73377

AS408

CAS 2378521-26-5

AS408 is a negative allosteric modulator of the β2-adrenergic receptor (β2AR) for both G-protein activation and arrestin recruitment (pKB=6.8, [35S]GTPγS binding assays), binds to a pocket formed by the membrane-facing surface of TM3 and TM5.

AS408 chemical structure
DC60732

VUF10166

CAS 155584-74-0

VUF10166 is a potent and high-affinity 5-HT3 receptor antagonist, with Ki values of 0.04 nM (5-HT3A) and 22 nM (5-HT3AB). VUF10166 inhibits 5-HT-induced responses at 5-HT3A and 5-HT3AB receptors at nanomolar concentrations. At 5-HT3 receptor, VUF10166 at higher concentrations also acts as a partial agonist, with an EC50 of 5.2 μM.

VUF10166 chemical structure
DC12124

Chlorantraniliprole

CAS 500008-45-7

In Vitro Chlorantraniliprole is an insecticide that potently and selectively activates insect ryanodine receptor. Chlorantraniliprole actions by release of intracellular Ca2+ stores mediated by the ryanodine receptor. Chlorantraniliprole is ∼300-fold less potent against ryanodine receptor (RyRs) in the mouse myoblast cell line, C2C12 (EC50, 14 μM), than in insect RyRs from Drosophila melanogaster and H. virescens (EC50, 40 nM, 50 nM), and shows little selectivity at the rat cell line RyR2 (EC50, >100 μM). In Vivo Chlorantraniliprole has low acute mammalian toxicity with an acute oral LD50 of >5000 mg/kg in rats, and little to no toxicity in 90-day studies, at dosing as high as 1500 mg/kg/day.

Chlorantraniliprole chemical structure
DC33730

FAUC-365

CAS 474432-66-1

FAUC 365 is a highly dopamine D3 receptor-selective antagonist with Ki values of 0.5 nM, 340, 2600, and 3600 nM at D3, D4.4, D2short, and D2Long receptors, respectively. FAUC 365 can be used for the research of schizophrenia, and Parkinson's disease.

FAUC-365 chemical structure
DC49661

AGI-43192

CAS 2377491-54-6

AGI-43192 is a potent inhibitor of methionine adenosyltransferase 2A (MAT2A). AGI-43192 is a potent, but limited brain-penetrant compound. AGI-43192 has the potential for exploring the effects of SAM modulation in the central nervous system (CNS) and research of cancer disease.

AGI-43192 chemical structure
DCC2512

Hdl376

CAS 147751-31-3

HDL376 is a scavenger receptor class B type I (SR-BI) inhibitor. HDL376 directly inhibits SR-BI-mediated lipid transport in cells and in liposomes reconstituted with purified SR-BI (IC50 = 0.22 μM). HDL376 can be used for the research of atherosclerotic coronary artery disease.

Hdl376 chemical structure
DC21007

Befiradol

CAS 208110-64-9

Befiradol (F13640, NLX 112) is a highly potent, selective 5-HT1A receptor agonist with Ki of 2.7 nM; exhibits agonist efficacy greater than for (±)8-OH-DPAT or buspirone; stimulates 'total G-proteins', but unlike (±)8-OH-DPAT and buspirone, more potent for Gαo activation, in rat hippocampal membranes; dose-dependently decreases extracellular 5-HT in the hippocampus and mPFC in rats, activates both 5-HT(1A) autoreceptors and postsynaptic 5-HT(1A) receptors in prefrontal cortex with a similar potency. Pain Discontinued

Befiradol chemical structure
Browse target & topic index A–Z (366)
11β-HSD (1)15-PGDH (2)5-HT Receptor (16)Acetyl-CoA Carboxylase (ACC) (3)Acetylcholinesterase (AChE) (2)Ack1 (TNK2) (1)Acyltransferase (1)ADC Cytotoxin (6)ADCs Linker/Click Chemistry (5)Adenosine Receptor (9)Adenylate Cyclase (2)Adrenergic Receptor (11)Akt (12)Alcoholism (2)Aldehyde Dehydrogenase (ALDH) (6)Allergy (5)Alzheimer Disease (13)Aminopeptidase (1)AMPK (8)Amyloids (4)Anaplastic Lymphoma Kinase (ALK) (9)Androgen Receptor (AR) (11)Anemia (4)Angiotensin Receptor (4)Antibody/Protein labeling dyes (1)Antifolate (2)Anxiety (1)Apoptosis Inducer (3)Arginase (1)Arp2/3 complex (1)Aryl hydrocarbon Receptor (AhR) (1)Asthma (5)Atherosclerosis (2)ATM/ATR (8)Aurora Kinase (10)Autophagy (6)Autophagy-related Protein (Atg) (2)Autotaxin (2)Bacterial (26)Bacterial Infection (17)Bcl-2 (14)Bcr-Abl (5)BCRP (1)Beta-catenin (4)Beta-secretase (BACE) (4)Blood Cancer (91)BMI-1 (1)Bone Cancer (6)Brain Cancer (6)Breast Cancer (30)Bromodomain (22)BTK (10)c-Fms (CSF1R) (5)c-Fos/AP-1 (1)c-Kit (6)c-Met (HGFR) (11)c-Myc (2)Calcium Channel (4)Calcium-sensing Receptor (CaSR) (1)CaMK (4)Cannabinoid Receptor (6)Carbonic Anhydrase (1)Carboxypeptidase (1)Casein Kinase (6)Caspase (4)Cathepsin (6)Cdc2-like Kinase (CLK) (1)CETP (2)CFTR (7)Checkpoint Kinase (Chk) (8)Chemokine Receptor (CCR and CXCR) (14)Chemotherapeutic Agents (19)Chloride Channel (1)CMV (2)CMV Infection (2)Colon Cancer (9)Complement System (1)COPD (3)CREB/CBP (2)CRF Receptor (2)CRISPR/Cas9 (1)Cushing Disease (1)Cyclin-dependent Kinase (CDK) (39)Cyclooxygenase (COX) (4)Cytochrome P450 (CYPs) (5)Depression (2)Dermatitis (2)Deubiquitinase (DUB) (7)Diabetes (20)Dipeptidyl Peptidase (DPP) (3)Discoidin Domain Receptor (DDR) (1)DNA Alkylator/Crosslinker (10)DNA Methyltransferase (DNMT) (1)DNA Repair Protein (1)DNA-PK (2)DNA/RNA Synthesis (5)Dopamine beta-hydroxylase (1)Dopamine Receptor (7)Drug Metabolite (1)Drug-Linker Conjugates (11)Dyes (4)DYRK (1)Dyslipidemia (9)E3 Ligase Ligand (6)E3 Ligase Ligand-Linker Conjugate (1)E3 Ubiquitin Ligase (4)Ebola Virus Infection (1)EGFR (32)Elastase (2)Endothelin Receptor (5)Enzymes substrates (13)Epigenetic Reader Domain (3)Epilepsy (4)ERK (4)Estrogen Receptor/ERR (13)Eukaryotic Initiation Factor (eIF) (2)Exportin-1 (CRM1,XPO1) (2)FABP (1)Factor Xa (5)Farnesoid X Receptor (FXR) (5)Farnesyl transferase (FTase) (1)Ferroptosis (6)FGFR (15)Fibrosis (5)FLT3 (6)Focal Adhesion Kinase (FAK) (11)Foxo1 (1)Free Fatty Acid Receptor (FFAR) (5)Fungal (2)Fungal Infection (1)GABA Receptor (13)Galectin (1)Gastric Cancer (8)Ghrelin Receptor (GHSR) (3)Glucagon Receptor (4)Glucokinase (2)Glucose Transporter (GLUT) (2)Glutamate Transporter (2)GPCR (1)GPER (GPR30) (1)GPR139 (1)GPR183 (EBI2) (2)GPR39 (1)GPR55 (1)GPR84 (1)GRK (GPCRK) (2)Growth Hormone Deficiency (2)GSK-3 (8)Guanylate Cyclase (3)HBV (1)HBV Infection (1)HCN Channel (2)HCV (8)HCV Infection (9)HDAC (38)Heart Arrhythmia (2)Heart Failure (5)Heat Shock Protein (HSP) (15)Hedgehog (Hh) (1)HIF/HIF Prolyl-hydroxylase (8)Histamine Receptor (6)Histone Acetyltransferase (HAT) (5)Histone Demethylase (11)Histone Methyltransferase (HMTase) (31)HIV (12)HIV Infection (11)HMG-CoA Reductase (HMGCR) (3)HSV (1)HSV Infection (1)Hypercholesterolemia (1)Hyperparathyroidism (1)Hypertension (8)IAP (1)IGF-1R (3)iGluR (15)Indoleamine 2,3-Dioxygenase (IDO) (4)Infection (1)Influenza (6)Influenza Virus (6)Insulin Receptor (2)Integrin (6)Interleukin Receptor (1)IRAK (2)IRE1 (4)Irritable Bowel Syndrome (2)Ischemia (1)Isocitrate Dehydrogenase (IDH) (5)ITK (1)IκB kinase (IKK) (7)JAK (32)JNK (3)Keap1-Nrf2 (6)Kidney Cancer (10)Kinesin (5)Kruppel-like Factor (KLF) (1)Kynurenine 3-Monooxygenase (KMO) (1)Leukotriene Receptor (1)LIM Kinase (LIMK) (3)Lipids fragment (1)Liver Cancer (6)Liver X Receptor (LXR) (3)LRRK2 (9)Lung Cancer (39)Lysophospholipid Receptor (12)LYTACs (3)mAChR (9)MALT1 (2)MAP4K (1)Matrix Metalloproteinase (MMP) (10)MDM2-p53 (9)MEK (MAP2K) (14)MEKK (MAP3K) (1)Melanocortin Receptor (2)MELK (1)mGluR (7)MicroRNA (1)Microtubule/Tubulin (5)Mineralocorticoid Receptor (MLR) (1)MITF (1)Mixed Lineage Kinase (MLK) (3)MNK (2)Molecular Glues (13)Monoamine Transporter (5)Monocarboxylate Transporter (MCT) (1)Monopolar Spindle 1 (Mps1/TTK) (3)mTOR (13)Multiple Sclerosis (6)Myosin (1)Na-K-Cl Cotransporter (NKCC) (2)nAChR (2)NADPH Oxidase (NOX) (2)NAMPT (3)Natural products (37)Neprilysin (1)Neurokinin Receptor (3)Neuropeptide Y Receptor (3)NF-κB (5)Nitric Oxide Synthase (NOS) (1)NOD-like Receptor (NLR) (3)Notch (2)Nucleoside Antimetabolite/Analog (10)Nur77 (NR4A1) (1)Obesity (1)Oct3/4 (1)Opioid Receptor (5)Orexin Receptor (7)Osteoporosis (2)Ovarian Cancer (14)Oxytocin Receptor (OXTR) (2)P-glycoprotein (P-gp) (3)p21-activated Kinase (PAK) (1)P2X Receptor (2)P2Y Receptor (1)p38 MAPK (10)p97/VCP (1)Pain (12)Pancreatic Cancer (10)Parasite (5)Parasite Infection (2)Parkinson Disease (2)PARP (19)PCSK9 (1)PD-1/PD-L1 (4)PDGFR (4)PDK1 (2)PEGn (1)PERK (2)PGE synthase (2)Phosphodiesterase (PDE) (9)Phospholipase (4)PI3K (32)PI4K (2)Piezo Channel (1)PIKfyve (3)Pim (9)PKC (12)PKD (1)Plasminogen Activator Inhibitor-1 (PAI-1) (3)Polo-like Kinase (PLK) (4)Porcupine (3)Potassium Channel (13)PPAR (13)Pregnane X Receptor (PXR) (1)Progesterone Receptor (2)Prostaglandin Receptor (11)Prostate Cancer (7)PROTACs (35)Protease-activated Receptor (PAR) (3)Proteasome (12)Protein Disulfide Isomerase (PDI) (1)Protein Phosphatase/PTP (6)Proton Pump (1)Psoriasis (5)RAD51 (1)Radioligand precursors (15)Raf (18)RAR/RXR (3)Ras (17)Renin (2)RET Tyrosine Kinase (c-RET) (3)Rheumatoid Arthritis (16)Ribosomal S6 Kinase (RSK) (5)RIG-I-like Receptor (RLR) (2)RIP kinase (7)ROCK (12)ROR (2)RSV (4)RSV Infection (3)RUNX1-CBFβ (1)S-nitrosoglutathione reductase (GSNOR) (1)Saccharides and Glycosides (1)Salt Inducible Kinase (SIK) (2)SARS-CoV (16)SARS-CoV Infection (34)Schizophrenia (4)Sexual Dysfunction (1)SGLT (4)Sigma Receptor (4)Sirtuin (9)Skin Cancer (13)Sleep Disorder (7)SMN2 Modulator (1)Smoothened (Smo) (9)Sodium Channel (12)Solid Tumors (35)Somatostatin Receptor (2)Sphingosine kinase (SphK) (2)Src (7)STAT (5)Stearoyl-CoA Desaturase (SCD) (1)Steatohepatitis (7)Sterol lipids (1)STING (14)Syk (6)T Cell Receptor (TCR) (1)TAK1 (2)TAM Receptor (Tyro3-Axl-Mer) (4)Taste Receptor (1)Telomerase (2)TGF beta Receptor (TGFBR) (12)Thrombin (3)Thrombosis (13)Thyroid Cancer (1)Thyroid Hormone Receptor (THR) (1)Thyrotropin Receptor (2)TNIK (1)Toll-like Receptor (TLR) (2)TOPK (1)Topoisomerase (11)TRAIL (1)Translocator Protein (TSPO) (1)Trk Receptor (4)TRP Channel (13)Tryptophan Hydroxylase (TPH) (1)Ubiquitin-activating Enzyme (E1) (2)Ubiquitin-conjugating Enzyme (E2) (2)Ulcer (1)ULK (3)Vasopressin Receptor (2)VEGFR (25)Vitamin D Receptor (VDR) (3)Wee1 (1)WNK Kinase (1)Wnt (5)Yes-associated Protein (YAP) (4)γ-secretase (5)

Cart

Request quotation